Effects of 7.5% CO2 challenge in generalized anxiety disorder
- PMID: 20233897
- DOI: 10.1177/0269881110364270
Effects of 7.5% CO2 challenge in generalized anxiety disorder
Abstract
We have previously developed a putative model of generalized anxiety disorder in healthy volunteers using a 20-minute 7.5% carbon dioxide (CO(2)) inhalation challenge. The aim of this study was to validate the 7.5% CO(2) paradigm by assessing its effects in patients with generalized anxiety disorder in a test-retest design. Twelve medication-free generalized anxiety disorder patients attended our lab for two study days. On each study day placebo (compressed air) and 7.5% CO(2) mixture were randomly administered over 20 min, at least 30 min apart, in a single blind, randomized, placebo-controlled cross-over design. Subjective ratings, cardiovascular measures and cortisol levels were collected throughout. CO(2) challenge significantly increased ratings for anxiety and other subjective symptoms associated with generalized anxiety disorder, compared with air. It also significantly increased systolic blood pressure on day 2, indicating increased autonomic arousal. There was no change between the two test days in mean anxiety rating scores, and there also appeared to be a correlation for individual scores on a number of the subjective measures. In conclusion, 20 min of 7.5% CO(2) gas inhalation increases anxiety responses in patients with generalized anxiety disorder, and this is reliable over time.
Similar articles
-
Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers.Depress Anxiety. 2005;21(1):18-25. doi: 10.1002/da.20048. Depress Anxiety. 2005. PMID: 15782425 Clinical Trial.
-
Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjects.J Psychopharmacol. 2005 Sep;19(5):494-503. doi: 10.1177/0269881105056533. J Psychopharmacol. 2005. PMID: 16166187 Clinical Trial.
-
Effect of nicotine on 35% CO2-induced anxiety: A study in healthy volunteers.Nicotine Tob Res. 2006 Aug;8(4):511-7. doi: 10.1080/14622200600789643. Nicotine Tob Res. 2006. PMID: 16920648 Clinical Trial.
-
The 35% carbon dioxide test in stress and panic research: overview of effects and integration of findings.Clin Psychol Rev. 2012 Apr;32(3):153-64. doi: 10.1016/j.cpr.2011.12.004. Epub 2012 Jan 5. Clin Psychol Rev. 2012. PMID: 22322014 Review.
-
Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD).J Psychopharmacol. 2011 Sep;25(9):1192-8. doi: 10.1177/0269881111408455. J Psychopharmacol. 2011. PMID: 21994314 Review.
Cited by
-
CO2 reactivity as a biomarker of exposure-based therapy non-response: study protocol.BMC Psychiatry. 2022 Dec 27;22(1):831. doi: 10.1186/s12888-022-04478-x. BMC Psychiatry. 2022. PMID: 36575425 Free PMC article.
-
Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function.Psychopharmacology (Berl). 2012 Sep;223(1):67-73. doi: 10.1007/s00213-012-2690-4. Epub 2012 Mar 29. Psychopharmacology (Berl). 2012. PMID: 22453547 Clinical Trial.
-
The relationship between dlPFC activity during unpredictable threat and CO2-induced panic symptoms.Transl Psychiatry. 2017 Nov 30;7(12):1266. doi: 10.1038/s41398-017-0006-5. Transl Psychiatry. 2017. PMID: 29213110 Free PMC article.
-
Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences.Neuropsychopharmacology. 2019 Nov;44(12):1999-2010. doi: 10.1038/s41386-019-0445-1. Epub 2019 Jun 21. Neuropsychopharmacology. 2019. PMID: 31226707 Free PMC article. Review.
-
Pregabalin for the treatment of generalized anxiety disorder: an update.Neuropsychiatr Dis Treat. 2013;9:883-92. doi: 10.2147/NDT.S36453. Epub 2013 Jun 24. Neuropsychiatr Dis Treat. 2013. PMID: 23836974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous